D
Doug King
Researcher at University College London
Publications - 3
Citations - 915
Doug King is an academic researcher from University College London. The author has contributed to research in topics: Genetic enhancement & Antibody. The author has an hindex of 2, co-authored 3 publications receiving 882 citations.
Papers
More filters
Journal ArticleDOI
Gene therapy of X-linked severe combined immunodeficiency by use of a pseudotyped gammaretroviral vector
H. Bobby Gaspar,Kathryn L. Parsley,Steven J. Howe,Doug King,Kimberly Gilmour,Kimberly Gilmour,Joanna Sinclair,Gaby Brouns,Manfred Schmidt,Christof von Kalle,Torben Barington,Marianne Antonius Jakobsen,Hans Ole Christensen,Abdulaziz Al Ghonaium,Harry N White,John L. Smith,Roland J. Levinsky,Robin R. Ali,Christine Kinnon,Adrian J. Thrasher,Adrian J. Thrasher +20 more
TL;DR: Gene therapy for SCID-X1 is a highly effective strategy for restoration of functional cellular and humoral immunity in patients with X-linked severe combined immunodeficiency.
Journal ArticleDOI
Successful reconstitution of immunity in ADA-SCID by stem cell gene therapy following cessation of PEG-ADA and use of mild preconditioning.
H. Bobby Gaspar,H. Bobby Gaspar,Emma Bjorkegren,Kate Parsley,Kate Parsley,Kimberly Gilmour,Kimberly Gilmour,Doug King,Joanna Sinclair,Fang Zhang,Aris Giannakopoulos,Stuart Adams,Lynette D. Fairbanks,Jane Gaspar,Lesley Henderson,Jin Hua Xu-Bayford,E. Graham Davies,Paul Veys,Christine Kinnon,Adrian J. Thrasher,Adrian J. Thrasher +20 more
TL;DR: It is document successful reconstitution of immune function in a child with the adenosine deaminase (ADA)-deficient form of severe combined immunodeficiency (SCID) following hematopoietic stem cell (HSC) gene therapy.
Journal ArticleDOI
Somatic Gene Therapy for ADA-SCID following cessation of PEG-ADA and use of a mild conditioning regime
Hubert B. Gaspar,Emma Bjorkegren,Katherine Parsley,Kimberly Gilmour,Jo Sinclair,Fang Zhang,Lynette D. Fairbanks,Doug King,Graham Davies,Paul Veys,Christine Kinnon,Adrian J. Thrasher +11 more
TL;DR: There is evidence of progressive immune recovery from gene modified cells and continued metabolic detoxification in one patient and further follow up and recruitment of more patients will determine the extent and longevity of immune recovery.